Cytokinetics, Incorporated
CYTK
$77.22
$2.413.22%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 19.36M | 17.76M | 1.94M | 66.77M | 1.58M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 19.36M | 17.76M | 1.94M | 66.77M | 1.58M |
| Cost of Revenue | 95.69M | 104.40M | 99.23M | 112.55M | 98.26M |
| Gross Profit | -76.33M | -86.64M | -97.30M | -45.79M | -96.68M |
| SG&A Expenses | 104.90M | 91.72M | 69.46M | 65.72M | 57.37M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 202.97M | 196.12M | 168.69M | 178.28M | 157.21M |
| Operating Income | -183.62M | -178.37M | -166.76M | -111.51M | -155.63M |
| Income Before Tax | -206.03M | -183.03M | -306.18M | -134.37M | -161.38M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -206.03M | -183.03M | -306.18M | -134.37M | -161.38M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -206.03M | -183.03M | -306.18M | -134.37M | -161.38M |
| EBIT | -183.62M | -178.37M | -166.76M | -111.51M | -155.63M |
| EBITDA | -180.24M | -175.51M | -164.08M | -109.22M | -153.33M |
| EPS Basic | -1.67 | -1.52 | -2.55 | -1.12 | -1.36 |
| Normalized Basic EPS | -1.04 | -0.95 | -0.96 | -0.70 | -0.85 |
| EPS Diluted | -1.67 | -1.52 | -2.55 | -1.12 | -1.36 |
| Normalized Diluted EPS | -1.04 | -0.95 | -0.96 | -0.70 | -0.85 |
| Average Basic Shares Outstanding | 123.27M | 120.10M | 119.98M | 119.46M | 118.50M |
| Average Diluted Shares Outstanding | 123.27M | 120.10M | 119.98M | 119.46M | 118.50M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |